Mira Pharmaceuticals (MIRA) Net Income towards Common Stockholders (2024 - 2025)
Mira Pharmaceuticals (MIRA) posted Net Income towards Common Stockholders of -$6.0 million for Q4 2025, up 73.64% sequentially from -$22.7 million in Q3 2025, and down 149.34% YoY from $12.1 million in Q4 2024.
Mira Pharmaceuticals (MIRA) Net Income towards Common Stockholders (2024 - 2025) Analysis & Trends
Mira Pharmaceuticals has reported Net Income towards Common Stockholders for 2 years, with the latest figure at -$6.0 million in Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 149.34% year-over-year to -$6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$28.7 million (down 545.38% YoY) and the FY2025 annual result came in at -$32.0 million, down 307.5% from the prior year.
- Net Income towards Common Stockholders rose to -$6.0 million in Q4 2025 per MIRA's latest filing, from -$22.7 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$2.0 million in Q3 2024 and troughed at -$22.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -238.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 583.63 Mn |
| 10 | Mira Pharmaceuticals | 18.47 Mn | 7.44 Mn | - | -5.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.98 Mn |
| Sep 30, 2025 | -22.69 Mn |
| Dec 31, 2024 | -2.40 Mn |
| Sep 30, 2024 | -2.04 Mn |